Analyst Price Targets — BNGO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 20, 2025 11:53 am | Jason McCarthy | Maxim Group | $8.00 | $3.77 | TheFly | Bionano Genomics upgraded to Buy from Hold at Maxim |
| August 28, 2024 6:51 am | Sung Ji Nam | Scotiabank | $1.00 | $0.51 | TheFly | Bionano Genomics downgraded at Scotiabank on limited capital market visibility |
| May 16, 2024 4:45 am | Mark Massaro | BTIG | $2.00 | $1.15 | StreetInsider | Bionano Genomics (BNGO) PT Lowered to $2 at BTIG |
| May 25, 2023 2:47 pm | Bionano Genomics's | EF Hutton | $175.00 | $65.00 | Benzinga | Bionano Genomics' Next-Gen Platform Set to Boost Throughput by 13x: Future of Cytogenetic Analysis Underway |
| December 12, 2022 8:34 am | — | BTIG | $350.00 | $219.00 | Benzinga | BTIG Assumes Bionano Genomics at Buy, Announces Price Target of $3.5 |
Latest News for BNGO
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO), effective July 20, 2026. In this role, Dr. Hastie will lead the company's global scientific strategy, innovation roadmap, and research initiatives, advancing Bionano's mission to expand the research…
SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared to the conference in 2025, consistent with expanding global adoption of OGM. Key highlights from studies of OGM presented at ESHG 2026: 35 studies featured OGM — a 67%…
SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that demonstrate the utility of optical genome mapping (OGM) for the detection and characterization of structural variants (SVs) in studies of reproductive health and prenatal genetic disorders. Reproductive disorders including…
Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNGO.
U.S. House Trading
No House trades found for BNGO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.